Hims & Hers Health (HIMS) Return on Capital Employed (2020 - 2026)
Hims & Hers Health (HIMS) reported Return on Capital Employed of 1.92% for Q1 2026, down 2309.0% on a YoY basis from 0.09% in Q1 2025, and down 132.57% sequentially from 5.9% in Q4 2025.
Hims & Hers Health (HIMS) Return on Capital Employed (2020 - 2026) Analysis & Trends
Hims & Hers Health (HIMS) has 7 years of Return on Capital Employed data on file, last reported at 1.92% in Q1 2026.
- For the quarter ending Q1 2026, Return on Capital Employed fell 2309.0% year-over-year to 1.92%; the trailing twelve-month figure through Mar 2026 stood at 1.92% (down 2309.0% YoY), and the FY2025 full-year result was 10.29%, down 725.0% from the prior year.
- Return on Capital Employed fell to 1.92% in Q1 2026, from 5.9% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 21.16% in Q1 2025 to a low of 26.53% in Q2 2022.
- A 5-year average of 4.95% and a median of 2.36% in 2024 frame the typical range for Return on Capital Employed.
- Across the five-year window, Return on Capital Employed surged 2377 bps in 2024 and tumbled 2309 bps in 2026, its largest moves.
- Tracing HIMS's Return on Capital Employed over 5 years: stood at 21.03% in 2022, then jumped by 59 bps to 8.69% in 2023, then jumped by 264 bps to 14.28% in 2024, then plunged by 59 bps to 5.9% in 2025, then sank by 133 bps to 1.92% in 2026.
- Business Quant data shows HIMS's Return on Capital Employed at 1.92% in Q1 2026, 5.9% in Q4 2025, and 7.17% in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 88.07 Bn | 86.20 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.75 Bn | 32.01 Bn | 1.97 Bn | 8.52% |
| 3 | Zoetis | 31.84 Bn | 29.90 Bn | 1.62 Bn | 27.36% |
| 4 | Takeda Pharmaceutical | 27.18 Bn | 23.12 Bn | 4.39 Bn | -1.50% |
| 5 | United Therapeutics | 23.09 Bn | 20.93 Bn | 648.10 Mn | 21.43% |
| 6 | RedHill Biopharma | 21.32 Bn | 21.32 Bn | - | - |
| 7 | Viatris | 19.96 Bn | 18.16 Bn | 1.16 Bn | 0.46% |
| 8 | Neurocrine Biosciences | 17.66 Bn | 16.34 Bn | 800.70 Mn | 20.04% |
| 9 | Elanco Animal Health | 12.44 Bn | 12.02 Bn | 785.00 Mn | 5.24% |
| 10 | Hims & Hers Health | 6.44 Bn | 5.69 Bn | 396.79 Mn | -1.92% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.92% |
| Dec 31, 2025 | 5.90% |
| Sep 30, 2025 | 7.17% |
| Jun 30, 2025 | 11.29% |
| Mar 31, 2025 | 21.16% |
| Dec 31, 2024 | 14.28% |
| Sep 30, 2024 | 11.04% |
| Jun 30, 2024 | 3.37% |
| Mar 31, 2024 | -2.36% |
| Dec 31, 2023 | -8.69% |
| Sep 30, 2023 | -12.73% |
| Jun 30, 2023 | -16.45% |
| Mar 31, 2023 | -20.01% |
| Dec 31, 2022 | -21.03% |
| Sep 30, 2022 | -25.00% |
| Jun 30, 2022 | -26.53% |
| Mar 31, 2022 | -23.68% |
| Dec 31, 2021 | -33.73% |
| Sep 30, 2021 | -29.60% |
| Jun 30, 2021 | -23.09% |